MannKind | MNKD - Operating Profit


MannKind reported $-68.23M in Operating Profit for its fiscal quarter ending in June of 2026.





Operating Profit Change Date
Adma Biologics USD 50.29M 12.46M Mar/2026
BioCryst Pharmaceuticals USD 98.46M 161.92M Jun/2026
Eli Lilly USD 12.46B 2.68B Jun/2026
Halozyme Therapeutics USD -63.72M 1.95M Jun/2026
Insmed USD -101.31M 98.97M Jun/2026
Karyopharm Therapeutics USD -26.76M 8.92M Mar/2026
MacroGenics USD -33.44M 21.34M Mar/2026
MannKind USD -68.23M 8.76M Jun/2026
Merck USD 840M 2.72B Jun/2026
Minerva Neurosciences USD -21.85M 17.48M Dec/2024
Novavax USD 20.94M 100.32M Dec/2025
Novo Nordisk DKK 5.25B 54.37B Jun/2026
Pfizer USD 667M 4.32B Jun/2026
Sanofi EUR 2.38B 449M Jun/2026
Xencor USD -36.6M 41.26M Jun/2026